SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
76,018
84,452
36,567
19,389
39,539
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
39,539
Operating Expenses
Research Development
133,369
114,866
65,728
65,618
67,198
Selling General and Administrative
57,063
46,736
27,200
26,330
19,197
Total Operating Expenses
190,432
161,602
92,928
91,948
86,395
Operating Income or Loss
-114,414
-77,150
-56,361
-72,559
-46,856
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-
-
-
887
431
Income Before Tax
-104,621
-68,889
-54,568
-71,672
-46,425
Income Tax Expense
-
0
0
-14
-5,722
Income from Continuing Operations
-104,621
-68,889
-54,568
-71,658
-40,703
Net Income
-103,941
-68,334
-54,568
-71,658
-40,703
Net Income available to common shareholders
-103,941
-68,334
-54,568
-71,658
-40,703
Reported EPS
Basic
-
-0.70
-0.70
-1.02
-0.58
Diluted
-
-0.70
-0.70
-1.02
-0.58
Weighted average shares outstanding
Basic
-
96,941
78,084
70,553
69,757
Diluted
-
96,941
78,084
70,553
69,757
EBITDA
-
-77,150
-56,361
-72,559
-46,856